Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy
We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy. In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction
Gespeichert in:
| Veröffentlicht in: | Circulation. Cardiovascular interventions 2014-08, Vol.7 (4), p.552-559 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 559 |
|---|---|
| container_issue | 4 |
| container_start_page | 552 |
| container_title | Circulation. Cardiovascular interventions |
| container_volume | 7 |
| creator | Poglajen, Gregor Sever, Matjaz Cukjati, Marko Cernelc, Peter Knezevic, Ivan Zemljic, Gregor Haddad, François Wu, Joseph C Vrtovec, Bojan |
| description | We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy.
In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction |
| doi_str_mv | 10.1161/CIRCINTERVENTIONS.114.001436 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1555249469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1555249469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-c705a25e771ee63491c6b9c7c194bcbc0584bfb5bd3b91fb3e37fa5286d6a2493</originalsourceid><addsrcrecordid>eNplUF1LwzAUDaK4Of0L0gcfBOlMmo-u4IvUqoWxwZy-hiRNWKVtatMh-_dmdu7Fp3s595x7zz0A3CA4RYih-zRfpflina0-ssU6Xy7ePEymECKC2QkYo4SgMGY4Oj32BI7AhXOfEHqYRedgFFGYxChJxoBnxmjVu8CaoO9E43RTWCW6ohRVkD5hchcoXVXDrK1E04u-tE1QNkHrO9146XfZb4LSqY2uSxX8im29s36-2V2CMyMqp68OdQLen7N1-hrOly95-jgPlbfdhyqGVERUxzHSmmGSIMVkomLlX5BKKkhnRBpJZYFlgozEGsdG0GjGCiYikuAJuB32tp392mrX89o78s5Fo-3WcUQp9TzC9tSHgao661ynDW-7shbdjiPI9xHzfxF7mPAhYi-_PlzayloXR_FfpvgHkVB7rA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1555249469</pqid></control><display><type>article</type><title>Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Poglajen, Gregor ; Sever, Matjaz ; Cukjati, Marko ; Cernelc, Peter ; Knezevic, Ivan ; Zemljic, Gregor ; Haddad, François ; Wu, Joseph C ; Vrtovec, Bojan</creator><creatorcontrib>Poglajen, Gregor ; Sever, Matjaz ; Cukjati, Marko ; Cernelc, Peter ; Knezevic, Ivan ; Zemljic, Gregor ; Haddad, François ; Wu, Joseph C ; Vrtovec, Bojan</creatorcontrib><description>We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy.
In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction <40%. In phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent transendocardial CD34(+) cell transplantation. Peripheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas of hibernating myocardium. Patients were followed up for 6 months after the procedure (phase 2). Two patients died during phase 1 and none during phase 2. The remaining 31 patients were 85% men, aged 57±6 years. In phase 1, we found no change in left ventricular ejection fraction (from 25.2±6.2% to 27.1±6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322±3411 to 3672±5165 pg/mL; P=0.75) or 6-minute walk distance (from 373±68 to 411±116 m; P=0.17). In contrast, in phase 2 there was an improvement in left ventricular ejection fraction (from 27.1±6.6% to 34.9±10.9%; P=0.001), increase in 6-minute walk distance (from 411±116 to 496±113 m; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672±5165 to 1488±1847 pg/mL; P=0.04). The average number of injected CD34(+) cells was 90.6±7.5×10(6). Higher doses of CD34(+) cells and a more diffuse distribution of transendocardial cell injections were associated with better clinical response.
Transendocardial CD34(+) cell transplantation may be associated with improved left ventricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise capacity in patients with ischemic cardiomyopathy. These effects seem to be particularly pronounced in patients receiving diffusely distributed cell injections and high-dose cell therapy.
http://www.clinicaltrials.gov. Unique identifier: NCT01350310.</description><identifier>ISSN: 1941-7640</identifier><identifier>EISSN: 1941-7632</identifier><identifier>DOI: 10.1161/CIRCINTERVENTIONS.114.001436</identifier><identifier>PMID: 25097199</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Antigens, CD34 - metabolism ; Blood Cells - pathology ; Blood Cells - transplantation ; Cardiomyopathies - therapy ; Cross-Over Studies ; Female ; Follow-Up Studies ; Granulocyte Colony-Stimulating Factor - metabolism ; Hematopoietic Stem Cell Mobilization ; Humans ; Ischemia - therapy ; Male ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stromal Cells - pathology ; Middle Aged ; Natriuretic Peptide, Brain - blood ; Peptide Fragments - blood ; Prospective Studies ; Recovery of Function ; Treatment Outcome</subject><ispartof>Circulation. Cardiovascular interventions, 2014-08, Vol.7 (4), p.552-559</ispartof><rights>2014 American Heart Association, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-c705a25e771ee63491c6b9c7c194bcbc0584bfb5bd3b91fb3e37fa5286d6a2493</citedby><cites>FETCH-LOGICAL-c436t-c705a25e771ee63491c6b9c7c194bcbc0584bfb5bd3b91fb3e37fa5286d6a2493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25097199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poglajen, Gregor</creatorcontrib><creatorcontrib>Sever, Matjaz</creatorcontrib><creatorcontrib>Cukjati, Marko</creatorcontrib><creatorcontrib>Cernelc, Peter</creatorcontrib><creatorcontrib>Knezevic, Ivan</creatorcontrib><creatorcontrib>Zemljic, Gregor</creatorcontrib><creatorcontrib>Haddad, François</creatorcontrib><creatorcontrib>Wu, Joseph C</creatorcontrib><creatorcontrib>Vrtovec, Bojan</creatorcontrib><title>Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy</title><title>Circulation. Cardiovascular interventions</title><addtitle>Circ Cardiovasc Interv</addtitle><description>We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy.
In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction <40%. In phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent transendocardial CD34(+) cell transplantation. Peripheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas of hibernating myocardium. Patients were followed up for 6 months after the procedure (phase 2). Two patients died during phase 1 and none during phase 2. The remaining 31 patients were 85% men, aged 57±6 years. In phase 1, we found no change in left ventricular ejection fraction (from 25.2±6.2% to 27.1±6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322±3411 to 3672±5165 pg/mL; P=0.75) or 6-minute walk distance (from 373±68 to 411±116 m; P=0.17). In contrast, in phase 2 there was an improvement in left ventricular ejection fraction (from 27.1±6.6% to 34.9±10.9%; P=0.001), increase in 6-minute walk distance (from 411±116 to 496±113 m; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672±5165 to 1488±1847 pg/mL; P=0.04). The average number of injected CD34(+) cells was 90.6±7.5×10(6). Higher doses of CD34(+) cells and a more diffuse distribution of transendocardial cell injections were associated with better clinical response.
Transendocardial CD34(+) cell transplantation may be associated with improved left ventricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise capacity in patients with ischemic cardiomyopathy. These effects seem to be particularly pronounced in patients receiving diffusely distributed cell injections and high-dose cell therapy.
http://www.clinicaltrials.gov. Unique identifier: NCT01350310.</description><subject>Adult</subject><subject>Antigens, CD34 - metabolism</subject><subject>Blood Cells - pathology</subject><subject>Blood Cells - transplantation</subject><subject>Cardiomyopathies - therapy</subject><subject>Cross-Over Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Granulocyte Colony-Stimulating Factor - metabolism</subject><subject>Hematopoietic Stem Cell Mobilization</subject><subject>Humans</subject><subject>Ischemia - therapy</subject><subject>Male</subject><subject>Mesenchymal Stem Cell Transplantation</subject><subject>Mesenchymal Stromal Cells - pathology</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain - blood</subject><subject>Peptide Fragments - blood</subject><subject>Prospective Studies</subject><subject>Recovery of Function</subject><subject>Treatment Outcome</subject><issn>1941-7640</issn><issn>1941-7632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplUF1LwzAUDaK4Of0L0gcfBOlMmo-u4IvUqoWxwZy-hiRNWKVtatMh-_dmdu7Fp3s595x7zz0A3CA4RYih-zRfpflina0-ssU6Xy7ePEymECKC2QkYo4SgMGY4Oj32BI7AhXOfEHqYRedgFFGYxChJxoBnxmjVu8CaoO9E43RTWCW6ohRVkD5hchcoXVXDrK1E04u-tE1QNkHrO9146XfZb4LSqY2uSxX8im29s36-2V2CMyMqp68OdQLen7N1-hrOly95-jgPlbfdhyqGVERUxzHSmmGSIMVkomLlX5BKKkhnRBpJZYFlgozEGsdG0GjGCiYikuAJuB32tp392mrX89o78s5Fo-3WcUQp9TzC9tSHgao661ynDW-7shbdjiPI9xHzfxF7mPAhYi-_PlzayloXR_FfpvgHkVB7rA</recordid><startdate>201408</startdate><enddate>201408</enddate><creator>Poglajen, Gregor</creator><creator>Sever, Matjaz</creator><creator>Cukjati, Marko</creator><creator>Cernelc, Peter</creator><creator>Knezevic, Ivan</creator><creator>Zemljic, Gregor</creator><creator>Haddad, François</creator><creator>Wu, Joseph C</creator><creator>Vrtovec, Bojan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201408</creationdate><title>Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy</title><author>Poglajen, Gregor ; Sever, Matjaz ; Cukjati, Marko ; Cernelc, Peter ; Knezevic, Ivan ; Zemljic, Gregor ; Haddad, François ; Wu, Joseph C ; Vrtovec, Bojan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-c705a25e771ee63491c6b9c7c194bcbc0584bfb5bd3b91fb3e37fa5286d6a2493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Antigens, CD34 - metabolism</topic><topic>Blood Cells - pathology</topic><topic>Blood Cells - transplantation</topic><topic>Cardiomyopathies - therapy</topic><topic>Cross-Over Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Granulocyte Colony-Stimulating Factor - metabolism</topic><topic>Hematopoietic Stem Cell Mobilization</topic><topic>Humans</topic><topic>Ischemia - therapy</topic><topic>Male</topic><topic>Mesenchymal Stem Cell Transplantation</topic><topic>Mesenchymal Stromal Cells - pathology</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain - blood</topic><topic>Peptide Fragments - blood</topic><topic>Prospective Studies</topic><topic>Recovery of Function</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poglajen, Gregor</creatorcontrib><creatorcontrib>Sever, Matjaz</creatorcontrib><creatorcontrib>Cukjati, Marko</creatorcontrib><creatorcontrib>Cernelc, Peter</creatorcontrib><creatorcontrib>Knezevic, Ivan</creatorcontrib><creatorcontrib>Zemljic, Gregor</creatorcontrib><creatorcontrib>Haddad, François</creatorcontrib><creatorcontrib>Wu, Joseph C</creatorcontrib><creatorcontrib>Vrtovec, Bojan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poglajen, Gregor</au><au>Sever, Matjaz</au><au>Cukjati, Marko</au><au>Cernelc, Peter</au><au>Knezevic, Ivan</au><au>Zemljic, Gregor</au><au>Haddad, François</au><au>Wu, Joseph C</au><au>Vrtovec, Bojan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy</atitle><jtitle>Circulation. Cardiovascular interventions</jtitle><addtitle>Circ Cardiovasc Interv</addtitle><date>2014-08</date><risdate>2014</risdate><volume>7</volume><issue>4</issue><spage>552</spage><epage>559</epage><pages>552-559</pages><issn>1941-7640</issn><eissn>1941-7632</eissn><abstract>We investigated the effects of transendocardial CD34(+) cell transplantation in patients with ischemic cardiomyopathy.
In a prospective crossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association class III and left ventricular ejection fraction <40%. In phase 1, patients were treated with medical therapy for 6 months. Thereafter, all patients underwent transendocardial CD34(+) cell transplantation. Peripheral blood CD34(+) cells were mobilized by granulocyte colony stimulating factor, collected via apheresis, and injected transendocardially in the areas of hibernating myocardium. Patients were followed up for 6 months after the procedure (phase 2). Two patients died during phase 1 and none during phase 2. The remaining 31 patients were 85% men, aged 57±6 years. In phase 1, we found no change in left ventricular ejection fraction (from 25.2±6.2% to 27.1±6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322±3411 to 3672±5165 pg/mL; P=0.75) or 6-minute walk distance (from 373±68 to 411±116 m; P=0.17). In contrast, in phase 2 there was an improvement in left ventricular ejection fraction (from 27.1±6.6% to 34.9±10.9%; P=0.001), increase in 6-minute walk distance (from 411±116 to 496±113 m; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672±5165 to 1488±1847 pg/mL; P=0.04). The average number of injected CD34(+) cells was 90.6±7.5×10(6). Higher doses of CD34(+) cells and a more diffuse distribution of transendocardial cell injections were associated with better clinical response.
Transendocardial CD34(+) cell transplantation may be associated with improved left ventricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise capacity in patients with ischemic cardiomyopathy. These effects seem to be particularly pronounced in patients receiving diffusely distributed cell injections and high-dose cell therapy.
http://www.clinicaltrials.gov. Unique identifier: NCT01350310.</abstract><cop>United States</cop><pmid>25097199</pmid><doi>10.1161/CIRCINTERVENTIONS.114.001436</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-7640 |
| ispartof | Circulation. Cardiovascular interventions, 2014-08, Vol.7 (4), p.552-559 |
| issn | 1941-7640 1941-7632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1555249469 |
| source | MEDLINE; American Heart Association Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Antigens, CD34 - metabolism Blood Cells - pathology Blood Cells - transplantation Cardiomyopathies - therapy Cross-Over Studies Female Follow-Up Studies Granulocyte Colony-Stimulating Factor - metabolism Hematopoietic Stem Cell Mobilization Humans Ischemia - therapy Male Mesenchymal Stem Cell Transplantation Mesenchymal Stromal Cells - pathology Middle Aged Natriuretic Peptide, Brain - blood Peptide Fragments - blood Prospective Studies Recovery of Function Treatment Outcome |
| title | Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T12%3A37%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20transendocardial%20CD34+%20cell%20transplantation%20in%20patients%20with%20ischemic%20cardiomyopathy&rft.jtitle=Circulation.%20Cardiovascular%20interventions&rft.au=Poglajen,%20Gregor&rft.date=2014-08&rft.volume=7&rft.issue=4&rft.spage=552&rft.epage=559&rft.pages=552-559&rft.issn=1941-7640&rft.eissn=1941-7632&rft_id=info:doi/10.1161/CIRCINTERVENTIONS.114.001436&rft_dat=%3Cproquest_cross%3E1555249469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1555249469&rft_id=info:pmid/25097199&rfr_iscdi=true |